Prognostic value of serum glycated albumin in acute coronary syndrome patients without standard modifiable cardiovascular risk factors.

ABSTRACT:

Background

Glycated albumin (GA) has been demonstrated to be associated with adverse outcomes in patients with acute coronary syndrome (ACS). However, as a specific subgroup of ACS, a significant proportion of patients with ACS without standard modifiable cardiovascular risk factors (SMuRFs) are currently being identified. The prognostic value of serum GA for adverse events in such patients remains unexplored. This study aims to evaluate the prognostic value of GA in predicting adverse outcomes in patients with ACS without SMuRFs.

Methods

This retrospective study involved 1,140 consecutive patients who were diagnosed with ACS without SMuRFs at the Beijing Anzhen Hospital between May 2018 and December 2020 and underwent coronary angiography. Each patient was followed up for a

SUBMITTER: Zhang X 

PROVIDER: S-EPMC11583742 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature